Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRefractory Lymphoblastic LymphomaRefractory B Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaRefractory T Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Down SyndromeRecurrent B Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionRadiation: 3-Dimensional Conformal Radiation TherapyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Lumbar Puncture
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT04546399
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
- Conditions
- Acute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 50
- Registration Number
- NCT04440267
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Wei Zhao
- Target Recruit Count
- 82
- Registration Number
- NCT04228393
- Locations
- 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Lymphoblastic Lymphoma, Childhood
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇦🇹
Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie, Graz, Austria
🇦🇹Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I, Innsbruck, Austria
🇦🇹Kepler Universitätsklinikum, Med Campus IV / Onkologie, Linz, Austria
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Testicular LeukemiaB Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaCentral Nervous System Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission Tomography
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇵🇷HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico
🇺🇸Miami Cancer Institute, Miami, Florida, United States
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 500
- Registration Number
- NCT03920813
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.